{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:04:45Z","timestamp":1762160685435},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.expneurol.2008.01.019","type":"journal-article","created":{"date-parts":[[2008,2,12]],"date-time":"2008-02-12T15:10:15Z","timestamp":1202829015000},"page":"172-179","source":"Crossref","is-referenced-by-count":32,"title":["Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets"],"prefix":"10.1016","volume":"211","author":[{"given":"K.A.","family":"Stockwell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Virley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Perren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.M.","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2008.01.019_bib1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.01.019_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.expneurol.2008.01.019_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.expneurol.2004.11.013","article-title":"Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates","volume":"192","author":"Bibbiani","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2008.01.019_bib4","first-page":"854","article-title":"Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys","volume":"272","author":"Blanchet","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2008.01.019_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1353-8020(02)00029-9","article-title":"Levodopa response motor complications\u2014GABA receptors and preproenkephalin expression in human brain","volume":"8","author":"Calon","year":"2002","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2008.01.019_bib6","first-page":"S70","article-title":"Molecular basis of levodopa-induced dyskinesias","volume":"47","author":"Calon","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2008.01.019_bib7","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S1471-1931(00)00026-4","article-title":"Dopamine-receptor stimulation: biobehavioral and biochemical consequences","volume":"23","author":"Calon","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2008.01.019_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuroscience.2004.10.026","article-title":"Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys","volume":"132","author":"Chen","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2008.01.019_bib9","first-page":"55","article-title":"Continuous subcutaneous lisuride infusions in Parkinson's disease","volume":"27","author":"Critchley","year":"1988","journal-title":"J. Neural Transm., Suppl."},{"key":"10.1016\/j.expneurol.2008.01.019_bib10","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.2165\/00003495-200464180-00015","article-title":"Cabergoline: a review of its use in the treatment of Parkinson's disease","volume":"64","author":"Curran","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.expneurol.2008.01.019_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nn0503-437","article-title":"L-DOPA, dyskinesia and striatal plasticity","volume":"6","author":"Dunnett","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2008.01.019_bib12","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1212\/WNL.58.suppl_1.S42","article-title":"Long-term studies of dopamine agonists","volume":"58","author":"Hubble","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.01.019_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00002512-200320110-00006","article-title":"Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison","volume":"20","author":"Inzelberg","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.expneurol.2008.01.019_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2006.10.005","article-title":"Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets","volume":"204","author":"Jackson","year":"2006","journal-title":"Exp. Neurol."},{"issue":"Suppl. 11","key":"10.1016\/j.expneurol.2008.01.019_bib15","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov. Disord."},{"issue":"Suppl. 2","key":"10.1016\/j.expneurol.2008.01.019_bib16","doi-asserted-by":"crossref","first-page":"II43","DOI":"10.1007\/PL00007760","article-title":"Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments","volume":"247","author":"Jenner","year":"2000","journal-title":"J. Neurol."},{"key":"10.1016\/j.expneurol.2008.01.019_bib17","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1212\/WNL.62.1_suppl_1.S47","article-title":"Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation","volume":"62","author":"Jenner","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.01.019_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.20276","article-title":"Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges","volume":"20","author":"Katzenschlager","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2008.01.019_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mds.1149","article-title":"Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)","volume":"16","author":"Maratos","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2008.01.019_bib20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/exnr.2002.8055","article-title":"Both short- and long-acting D-1\/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)","volume":"179","author":"Maratos","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2008.01.019_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","article-title":"Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update","volume":"45","author":"Nyholm","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.expneurol.2008.01.019_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00002826-200305000-00010","article-title":"Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets","volume":"26","author":"Nyholm","year":"2003","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2008.01.019_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","article-title":"Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease","volume":"64","author":"Nyholm","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.01.019_bib24","first-page":"11","article-title":"Motor complications associated with chronic levodopa therapy in Parkinson's disease","volume":"39","author":"Obeso","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.01.019_bib25","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","article-title":"Levodopa motor complications in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2008.01.019_bib26","first-page":"S13","article-title":"The evolution and origin of motor complications in Parkinson's disease","volume":"55","author":"Obeso","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.01.019_bib27","first-page":"S22","article-title":"Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model","volume":"47","author":"Obeso","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2008.01.019_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mds.20724","article-title":"Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study","volume":"21","author":"Oertel","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2008.01.019_bib29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2008.01.019_bib30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2008.01.019_bib31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.870130207","article-title":"De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset","volume":"13","author":"Pearce","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2008.01.019_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/mds.10031","article-title":"Clinical\u2013pathological study of levodopa complications","volume":"17","author":"Rajput","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2008.01.019_bib33","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2008.01.019_bib34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2165\/00023210-200519110-00006","article-title":"Rotigotine: in Parkinson's disease","volume":"19","author":"Reynolds","year":"2005","journal-title":"CNS Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2008.01.019_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","article-title":"Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group","volume":"55","author":"Rinne","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.expneurol.2008.01.019_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mds.870110203","article-title":"An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets","volume":"11","author":"Smith","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2008.01.019_bib37","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/mds.10200","article-title":"Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation","volume":"17","author":"Smith","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2008.01.019_bib38","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1212\/WNL.62.1_suppl_1.S56","article-title":"Continuous dopaminergic stimulation in early and advanced Parkinson's disease","volume":"62","author":"Stocchi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.01.019_bib39","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/brain\/awf214","article-title":"Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease","volume":"125","author":"Stocchi","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2008.01.019_bib40","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archneur.62.6.905","article-title":"Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study","volume":"62","author":"Stocchi","year":"2005","journal-title":"Arch. Neurol."},{"issue":"Pt 1B","key":"10.1016\/j.expneurol.2008.01.019_bib41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/brain\/114.1.601","article-title":"Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients","volume":"114","author":"Vaamonde","year":"1991","journal-title":"Brain"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448860800037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448860800037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T20:28:19Z","timestamp":1546288099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448860800037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S001448860800037X"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2008.01.019","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}